Duke Vaccine Manufacturing and Toxicology Core


The Duke Human Vaccine Institute (DHVI) commissioned a manufacturing facility for HIV vaccine development in 2016; soon thereafter, the manufacturing facility began onboarding influenza vaccine and therapeutic platforms. This facility hosts the CIVICs Vaccine Manufacturing and Toxicology Core, which follows Good Manufacturing Practices (GMP) to ensure patient safety and product quality. The Core’s GMP Program is designed to meet the demand for fast, iterative, early-phase process development and clinical manufacturing as an enabler for research organizations. The Core uses flexible, non-fixed equipment, to enable rapid layout configuration changes that keep pace with the shifting needs of the manufacturing facility. Additionally, the team uses single-use, closed system unit operations in manufacturing. The GMP team includes experts in the field with extensive experience in industry before joining the DHVI and works collaboratively with third party entities routinely for toxicology studies and has its own regulatory office of Investigational New Drug (IND) and Investigator’s Brochure (IB) submissions.

Principal Investigator


Duke Human Vaccine Institute (DHVI)

Key Personnel

Program Managers

Other Staff

  • Tom Jacobsen, PhD, GMP Scientist/Lead, Upstream Process Development and Cell Line Development, Duke Human Vaccine Institute
  • Althaf Hussain, PhD, Senior Director of Product Development, Analytical Sciences and cGMP Manufacturing, Duke Human Vaccine Institute
  • Myles Lindsay, PhD, Director, Downstream Process Development, Duke Human Vaccine Institute
  • Diana Martik, PhD, Associate Director, GMP Analytics, Duke Human Vaccine Institute
  • Maureen Maughan, PhD, Director of mRNA Program and cGMP Product Integration, Duke Human Vaccine Institute
  • Daniel Ozaki, MPH, Director, GMP Quality, Duke Human Vaccine Institute
  • Daniel Tonkin, PhD, Regulatory Affairs Scientist, Duke Human Vaccine Institute

Good manufacturing practices (GMP) are standard practices that are set by agencies that authorize and regulate industries that manufacture and sell foods, drugs and medical devices. GMP practices ensure that the vaccines created by CIVICs are safe for human trials. The Duke Vaccine Manufacturing and Toxicology Core has a state of the art GMP Facility, which can be virtually toured here.